NZ312502A - Clostridium difficile toxins as mucosal adjuvants - Google Patents

Clostridium difficile toxins as mucosal adjuvants

Info

Publication number
NZ312502A
NZ312502A NZ312502A NZ31250296A NZ312502A NZ 312502 A NZ312502 A NZ 312502A NZ 312502 A NZ312502 A NZ 312502A NZ 31250296 A NZ31250296 A NZ 31250296A NZ 312502 A NZ312502 A NZ 312502A
Authority
NZ
New Zealand
Prior art keywords
clostridium difficile
mucosal adjuvants
difficile toxins
mammal
antigen
Prior art date
Application number
NZ312502A
Other languages
English (en)
Inventor
William D Thomas
Thomas P Monath
Zhenxi Zhang
Francisco Javier Torres-Lopez
Wende Lei
David M Lyerly
James S Moncrieff
Original Assignee
Oravax Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27053134&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ312502(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US08/543,708 external-priority patent/US5919463A/en
Application filed by Oravax Inc filed Critical Oravax Inc
Publication of NZ312502A publication Critical patent/NZ312502A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
NZ312502A 1995-07-07 1996-07-01 Clostridium difficile toxins as mucosal adjuvants NZ312502A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US49938495A 1995-07-07 1995-07-07
US08/543,708 US5919463A (en) 1995-07-07 1995-10-16 Clostridium difficle toxins as mucosal adjuvants
PCT/US1996/011142 WO1997002836A1 (en) 1995-07-07 1996-07-01 Clostridium difficile toxins as mucosal adjuvants

Publications (1)

Publication Number Publication Date
NZ312502A true NZ312502A (en) 1999-03-29

Family

ID=27053134

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ312502A NZ312502A (en) 1995-07-07 1996-07-01 Clostridium difficile toxins as mucosal adjuvants

Country Status (9)

Country Link
EP (1) EP0837692B1 (enExample)
JP (1) JPH11509200A (enExample)
CN (1) CN1195297A (enExample)
AT (1) ATE195878T1 (enExample)
AU (1) AU720567B2 (enExample)
CA (1) CA2226339A1 (enExample)
DE (1) DE69610106D1 (enExample)
NZ (1) NZ312502A (enExample)
WO (1) WO1997002836A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9626864D0 (en) * 1996-12-24 1997-02-12 Smithkline Beecham Biolog Vaccine
EP1000155A1 (en) * 1997-06-20 2000-05-17 QUEEN MARY & WESTFIELD COLLEGE Immunogenic fragments of toxin a of clostridium difficile
EP1568378B1 (en) * 1997-10-20 2016-03-16 Sanofi Pasteur Biologics, LLC Immunization against Clostridium difficile disease
DE69829400T2 (de) 1997-10-20 2006-04-13 Acambis, Inc., Cambridge Passive immunisierung gegen durch clostridium difficile verursachte krankheit
US6969520B2 (en) 1997-10-20 2005-11-29 Acambis Inc. Active immunization against clostridium difficile disease
WO1999049890A1 (en) * 1998-03-31 1999-10-07 Daewoong Pharmaceutical Co., Ltd. A preventive and therapeutic vaccine for helicobacter pylori-associated diseases
US6733760B1 (en) 1999-04-09 2004-05-11 Techlab, Inc. Recombinant toxin A/toxin B vaccine against Clostridium difficile
JP2002542169A (ja) * 1999-04-09 2002-12-10 テクラブ， インコーポレイテッド Ｃｌｏｓｔｒｉｄｉｕｍｄｉｆｆｉｃｉｌｅに対する、組換え毒素Ａ／毒素Ｂワクチン
WO2000061761A2 (en) * 1999-04-09 2000-10-19 Techlab, Inc. Recombinant clostridium toxin a protein carrier for polysaccharide conjugate vaccines
MX343356B (es) 2010-03-30 2016-11-03 Pfenex Inc * Toxinas proteicas recombinantes de alto nivel de expresion.
SI2753352T2 (sl) 2010-09-03 2022-10-28 Valneva Austria Gmbh Izoliran polipeptid proteinov toksina a in toksina b c. difficile in njegova uporaba
JP5917682B2 (ja) 2011-04-22 2016-05-18 ワイス・エルエルシー 変異体クロストリジウム・ディフィシル毒素に関する組成物およびその方法
PL3138916T3 (pl) * 2011-05-27 2019-11-29 Glaxosmithkline Biologicals Sa Kompozycja immunogenna
IN2014CN04071A (enExample) 2011-12-08 2015-10-23 Novartis Ag
BR122016023101B1 (pt) 2012-10-21 2022-03-22 Pfizer Inc Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4944942A (en) * 1987-08-27 1990-07-31 Mobay Corporation Intranasal vaccination of horses with inactivated microorganisms or antigenic material
JP2849632B2 (ja) * 1988-04-08 1999-01-20 社団法人北里研究所 ワクチン製剤
US5601823A (en) * 1989-10-31 1997-02-11 Ophidian Pharmaceuticals, Inc. Avian antitoxins to clostridium difficle toxin A
IL106362A (en) * 1992-07-16 1998-12-06 Oxford University A system for launching multiple particle antigens
GB9305919D0 (en) * 1993-03-22 1993-05-12 Health Lab Service Board Botulinum toxin polypeptides and their use as vaccines

Also Published As

Publication number Publication date
WO1997002836A1 (en) 1997-01-30
AU720567B2 (en) 2000-06-08
CN1195297A (zh) 1998-10-07
DE69610106D1 (de) 2000-10-05
AU6404796A (en) 1997-02-10
ATE195878T1 (de) 2000-09-15
EP0837692B1 (en) 2000-08-30
EP0837692A4 (enExample) 1998-04-29
JPH11509200A (ja) 1999-08-17
EP0837692A1 (en) 1998-04-29
CA2226339A1 (en) 1997-01-30

Similar Documents

Publication Publication Date Title
NZ312502A (en) Clostridium difficile toxins as mucosal adjuvants
IL107026A0 (en) Antigen of hybrid m protein and carrier for group a streptococcal vaccine
ATE127345T1 (de) Stressproteine und verwendungen dafür.
AU3233795A (en) Mutant enterotoxin effective as a non-toxic oral adjuvant
EP0652758A4 (en) VACCINES AGAINST DIPHTERY TOXIN.
EP1170016A3 (en) Urease-based vaccine against helicobacter infection
TR199801722T2 (xx) Peptit imm�nojenler.
AU1934088A (en) Saponin adjuvant
AP2000001886A0 (en) Group B streptococcus antigens.
AU5162201A (en) Immunostimulant compositions comprising an aminoalkyl glucosaminide phosphate and qs-21
AUPM885194A0 (en) Synthetic peptides and vaccines comprising same
AU2917697A (en) Dendritic cell receptor
WO1994010317A3 (en) Conjugate vaccine against group b streptococcus
HUP9801223A2 (hu) Eljárás specifikus antigénekre adott antitest válasz fokozására interleukin-10-zel
ES483374A1 (es) Procedimiento para modificar las propiedades antigenas de unantigeno de polen de la hierba
KR100218138B1 (en) Methods and vaccines comprising surface-active copolymers
AU4545096A (en) Polypeptide fragments capable of competition with streptococcus mutans antigen i/ii
DK0725653T3 (da) Vaccinepræparater
ZA919907B (en) Use of il-4 to enhance immune response to immunogens in vaccines
ATE234109T1 (de) Cetp zur erhöhung des hdl-cholesterol-gehalts
SE9604322D0 (sv) Bacterial antigens and vaccine compositions II
WO2002004497A3 (en) Multiple antigenic peptides immunogenic against streptococcus pneumoniae
NZ333191A (en) Human dendritic cell receptor DEC-205
NO980721L (no) Vaksiner
MX9708226A (es) Vacunas que contienen una saponina y un esterol.

Legal Events

Date Code Title Description
RENW Renewal (renewal fees accepted)